Videos
Colorectal Cancer
Scott Kopetz, MD, PhD, discusses the treatment of patients with colorectal cancer and how it differs from other cancer regimens.
Benjamin P. Levy, MD, discusses biomarkers that have led to the development therapies with high response rates in lung cancer.
Andre Goy, MD, discusses the current treatments, specifically Bruton’s tyrosine kinase, for patients with mantle cell lymphoma and what the efficacy has been with this type of treatment.
Tatyana Feldman, MD, director of T cell program at the John Theurer Cancer Center, Hackensack Meridian Health, discusses how research is now building upon the positive results from the phase III ECHELON-1 study, which was presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.<br />
Neeraj Agarwal, MD, discusses the efficacy of cabozantinib and atezolizumab in the COSMIC-021 study.
David Polsky, MD, PhD, discusses methods to identify circulating tumor DNA in patients with melanoma.
Jason Westin, MD, MS, FACP, discusses the current treatment options for patients with diffuse large B-cell lymphoma that are available besides rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.
Zofia Piotrowska, MD, MHS, discusses the rationale for conducting the FLAURA trial in patients with <em>EGFR</em>-mutant non–small cell lung cancer and how the use of osimertinib impacted the treatment landscape for this patient population.
Courtney D. DiNardo, MD, MSCE, discusses what is on the horizon for the acute myeloid leukemia setting.
Thomas Powles, MD, MBBS, MRCP, discusses how researchers are working to optimize treatment with immune checkpoint inhibitors for patients with urothelial carcinoma.
Sagar Lonial, MD, FACP, explains the 2 main challenges physicians face when they are treating patients with smoldering multiple myeloma.
David J. Pinato, MD, PhD, discusses the importance of utilizing a multidisciplinary approach when treating patients with hepatocellular carcinoma and how this approach helps optimize patient outcomes now as well as how it will help in the near future as more therapies emerge.
David Miklos, MD, PhD, describes the toxicity profile of KTE-X19, a chimeric antigen receptor T-cell therapy, in the ZUMA-2 trial.
Julie R. Brahmer, MD, discusses the role of molecular testing for patients with lung cancer and why this is particularly important for those with early-stage disease.
Alexey V. Danilov, MD, PhD, discusses important studies in the chronic lymphocytic leukemia space and questions whether combination or sequential therapy is better for patients with chronic lymphocytic leukemia.
A 60-Year Old Man With Untreated Stage IV EGFR-Mutated Non-Small Cell Lung Cancer
Van K. Morris, MD, describes the novel treatments he is excited about in the treatment landscapes for colorectal and anal cancers right now.
Floor J. Backes, MD, discusses the immunotherapeutic options available for treatment of patients with ovarian cancer.
Jorge E. Cortes, MD, explains how ruxolitinib is used to treat various myeloproliferative neoplasms and which patients require other therapies.
Sameer Desai, MD, discusses the changing treatment landscape for lymphomas.
Elizabeth A. Mittendorf, MD, PhD, discusses different data looking at sequencing therapies and why it is important in the breast cancer setting.<br />
Stephen J. Freedland, MD, discussed an analysis real-world patients with metastatic castration-resistant prostate cancer, which he presented at the 2020 Genitourinary Cancers Symposium.